BioSpace News Archive

Vizient, Inc. today announced it has signed an agreement with Pfizer, Inc. to add six drugs identified as “essential medications” to its Novaplus® Enhanced Supply Program, part of Vizient’s private label pharmacy solution.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that Chief Executive Officer Myron Holubiak will deliver a virtual presentation at the Life Sciences Investor Forum on Thursday, June 25, 2020 at 11:00 AM ET.

The following quote is attributed to Steven M. Solomon, D.V.M., M.P.H., Director of the FDA’s Center for Veterinary Medicine.

LUNGevity Foundation is partnering with patient-led group EGFR Resisters on the EGFR-Positive Lung Cancer Research Award Program. EGFR Resisters was founded in 2017 by EGFR-positive lung cancer patients to drive important research questions and fund novel research and clinical trials into their mutation that may ultimately save and improve the quality of their lives

Catalyst Biosciences, Inc., announced the closing of an underwritten public offering of 4,615,384 shares of its common stock, offered at a price of $6.50 per share to the public.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today provided a research and development (R&D) update regarding the company’s innovative portfolio directed against RAS cancers.

Amgen (NASDAQ: AMGN) today announced it is supporting the further study of AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor, for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy.

Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpoints

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that it received notice from The NASDAQ Stock Market LLC on June 18, 2020 indicating that the Company has regained compliance with NASDAQ Listing Rule 5450, which requires the Company’s common stock to maintain a minimum bid price of $1.00 per share.

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the fourth quarter and fiscal year ended March 31, 2020.